Suppr超能文献

Waldenström's macroglobulinemia front line treatment.

作者信息

Tedeschi Alessandra, Frustaci Anna Maria

机构信息

Division of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000222. eCollection 2019 Jun.

Abstract
摘要

相似文献

1
Waldenström's macroglobulinemia front line treatment.
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000222. eCollection 2019 Jun.
3
Novel agents in the treatment of Waldenström's macroglobulinemia.
Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206. doi: 10.3816/clm.2007.s.023.
6
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
Haematologica. 2010 Mar;95(3):470-5. doi: 10.3324/haematol.2009.010348. Epub 2009 Nov 10.
7
Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Optom Vis Sci. 2005 Jul;82(7):573-8. doi: 10.1097/01.opx.0000171333.64652.a4.
8
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
9
L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
PLoS One. 2013 Nov 5;8(11):e80088. doi: 10.1371/journal.pone.0080088. eCollection 2013.
10
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Best Pract Res Clin Haematol. 2016 Jun;29(2):187-193. doi: 10.1016/j.beha.2016.08.015. Epub 2016 Sep 4.

本文引用的文献

2
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.
3
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25.
4
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.
5
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.
6
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.
7
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Clin Cancer Res. 2018 Jul 15;24(14):3247-3252. doi: 10.1158/1078-0432.CCR-18-0152. Epub 2018 Apr 16.
9
Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
Br J Haematol. 2017 Oct;179(1):106-115. doi: 10.1111/bjh.14828. Epub 2017 Jul 5.
10
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Br J Haematol. 2017 Jun;177(5):717-725. doi: 10.1111/bjh.14743. Epub 2017 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验